[贝达喹啉治疗特殊人群耐药结核病的安全性和有效性研究进展]。

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases Pub Date : 2023-06-12 DOI:10.3760/cma.j.cn112147-20230103-00003

Y P Zhang, Y Y Niu, P J Tang

{"title":"[贝达喹啉治疗特殊人群耐药结核病的安全性和有效性研究进展]。","authors":"Y P Zhang, Y Y Niu, P J Tang","doi":"10.3760/cma.j.cn112147-20230103-00003","DOIUrl":null,"url":null,"abstract":"Antimicrobial resistance in Mycobacterium tuberculosis is a serious threat to global tuberculosis(TB) control. WHO listed bedaquiline as one of the first-choice drugs for the treatment of MDR/RR-TB in 2018. Bedaquiline is marketed for adult patients with MDR-TB and XDR-TB. However, there are few studies of bedaquiline in adolescents, pregnant women, the elderly, and other special populations with drug-resistant TB. This paper aimed to review the effectiveness and safety of bedaquiline in the treatment of special populations of drug-resistant TB for the clinical use.","PeriodicalId":23961,"journal":{"name":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","volume":"46 6","pages":"619-624"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Progress on the safety and efficacy of bedaquiline for the treatment of drug-resistant tuberculosis in special populations].\",\"authors\":\"Y P Zhang, Y Y Niu, P J Tang\",\"doi\":\"10.3760/cma.j.cn112147-20230103-00003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Antimicrobial resistance in Mycobacterium tuberculosis is a serious threat to global tuberculosis(TB) control. WHO listed bedaquiline as one of the first-choice drugs for the treatment of MDR/RR-TB in 2018. Bedaquiline is marketed for adult patients with MDR-TB and XDR-TB. However, there are few studies of bedaquiline in adolescents, pregnant women, the elderly, and other special populations with drug-resistant TB. This paper aimed to review the effectiveness and safety of bedaquiline in the treatment of special populations of drug-resistant TB for the clinical use.\",\"PeriodicalId\":23961,\"journal\":{\"name\":\"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases\",\"volume\":\"46 6\",\"pages\":\"619-624\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn112147-20230103-00003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112147-20230103-00003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

结核分枝杆菌的抗微生物药物耐药性是对全球结核病控制的严重威胁。世卫组织于2018年将贝达喹啉列为治疗耐多药/耐药结核病的首选药物之一。贝达喹啉用于耐多药结核病和广泛耐药结核病的成人患者。然而，关于贝达喹啉在青少年、孕妇、老年人和其他耐药结核病特殊人群中的应用的研究很少。本文旨在综述贝达喹啉治疗特殊耐药人群结核病的有效性和安全性，供临床使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Progress on the safety and efficacy of bedaquiline for the treatment of drug-resistant tuberculosis in special populations].

Antimicrobial resistance in Mycobacterium tuberculosis is a serious threat to global tuberculosis(TB) control. WHO listed bedaquiline as one of the first-choice drugs for the treatment of MDR/RR-TB in 2018. Bedaquiline is marketed for adult patients with MDR-TB and XDR-TB. However, there are few studies of bedaquiline in adolescents, pregnant women, the elderly, and other special populations with drug-resistant TB. This paper aimed to review the effectiveness and safety of bedaquiline in the treatment of special populations of drug-resistant TB for the clinical use.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

自引率

0.00%

发文量